...
首页> 外文期刊>Infection and Drug Resistance >Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B
【24h】

Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

机译:HBeAg阳性慢性乙型肝炎患者接受PEG干扰素-α治疗后,较高的基线病毒多样性与较低的HBsAg下降相关

获取原文

摘要

Background: Viral diversity seems to predict treatment outcomes in certain viral infections. The aim of this study was to evaluate the association between baseline intra-patient viral diversity and hepatitis B surface antigen (HBsAg) decline following PEGylated interferon-alpha (Peg-IFN-α) therapy. Patients and methods: Twenty-six HBeAg-positive patients who were treated with Peg-IFN-α were enrolled. Nested polymerase chain reaction (PCR), cloning, and sequencing of the hepatitis B virus S gene were performed on baseline samples, and normalized Shannon entropy (Sn) was calculated as a measure of small hepatitis B surface protein (SHBs) diversity. Multiple regression analysis was used to estimate the association between baseline Sn and HBsAg decline. Results: Of the 26 patients enrolled in the study, 65.4% were male and 61.5% were infected with hepatitis B virus genotype B. The median HBsAg level at baseline was 4.5 log10 IU/mL (interquartile range: 4.1–4.9) and declined to 3.0 log10 IU/mL (interquartile range: 1.7–3.9) after 48?weeks of Peg-IFN-α treatment. In models adjusted for baseline alanine aminotransferase (ALT) and HBsAg, the adjusted coefficients (95% CI) for ΔHBsAg and relative percentage HBsAg decrease were ?1.3 (?2.5, ?0.2) log10 IU/mL for higher SHBs diversity (Sn≥0.58) patients and ?26.4% (?50.2%, ?2.5%) for lower diversity (Sn<0.58) patients. Further analysis showed that the “a” determinant upstream flanking region and the first loop of the “a” determinant (nucleotides 341–359, 371–389, and 381–399) were the main sources of higher SHBs diversity. Conclusion: Baseline intra-patient SHBs diversity was inverse to HBsAg decline in HBeAg-positive chronic hepatitis B (CHB) patients receiving Peg-IFN-α monotherapy. Also, more sequence variations within the “a” determinant upstream flanking region and the first loop of the “a” determinant were the main sources of the higher SHBs diversity.
机译:背景:病毒多样性似乎可以预测某些病毒感染的治疗结果。这项研究的目的是评估聚乙二醇化干扰素-α(Peg-IFN-α)治疗后基线患者体内病毒多样性与乙型肝炎表面抗原(HBsAg)下降之间的关联。患者和方法:招募了26例接受Peg-IFN-α治疗的HBeAg阳性患者。对基线样本进行了巢式聚合酶链反应(PCR),乙型肝炎病毒S基因的克隆和测序,并计算了标准化的香农熵(Sn)作为衡量乙型肝炎表面蛋白(SHBs)多样性的指标。多元回归分析用于估计基线Sn和HBsAg下降之间的关联。结果:在该研究的26名患者中,男性65.4%,乙型肝炎病毒B型感染61.5%。基线时的HBsAg中位数为4.5 log 10 IU / mL(四分位数范围) :4.1–4.9),在接受Peg-IFN-α治疗48周后降至3.0 log 10 IU / mL(四分位间距:1.7–3.9)。在校正了基线丙氨酸转氨酶(ALT)和HBsAg的模型中,校正后的ΔHBsAg系数和HBsAg相对减少百分比的系数(95%CI)为<1.3(?2.5,?0.2)log 10 IU / mL SHBs多样性较高(Sn≥0.58)的患者为26.4%(Sn <0.58),2.5%为较低多样性(Sn <0.58)的患者。进一步的分析表明,“ a”决定簇上游侧翼区域和“ a”决定簇的第一个环(核苷酸341–359、371–389和381–399)是SHBs多样性较高的主要来源。结论:接受Peg-IFN-α单药治疗的HBeAg阳性慢性乙型肝炎(CHB)患者的基线住院患者SHBs多样性与HBsAg下降成反比。同样,“ a”决定簇上游侧翼区域内更多的序列变异和“ a”决定簇的第一环是较高SHB多样性的主要来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号